Viridian Therapeutics Announces Positive Phase 3 Trial Results

Elegrobart drug shows promise in treating active thyroid eye disease

Mar. 30, 2026 at 12:25pm

Got story updates? Submit your updates here. ›

Viridian Therapeutics, a biopharmaceutical company, has announced positive topline results from its Phase 3 REVEAL-1 clinical trial of the drug Elegrobart for the treatment of active thyroid eye disease. The trial evaluated the safety and efficacy of Elegrobart in patients with the condition.

Why it matters

Thyroid eye disease is a debilitating autoimmune disorder that can lead to bulging eyes, double vision, and in severe cases, vision loss. The positive results from Viridian's trial could pave the way for a new treatment option for patients suffering from this difficult-to-manage condition.

The details

The REVEAL-1 trial enrolled 310 patients with active thyroid eye disease. Patients were randomized to receive either Elegrobart or a placebo. The primary endpoint was the proportion of patients who achieved a clinically meaningful improvement in proptosis, or eye bulging, at week 24. The trial met this endpoint, with a significantly higher proportion of Elegrobart-treated patients achieving the primary outcome compared to placebo.

  • The REVEAL-1 trial was conducted between January 2024 and December 2025.
  • Viridian announced the positive topline results on March 30, 2026.

The players

Viridian Therapeutics

A biopharmaceutical company focused on developing treatments for rare and underserved diseases.

Elegrobart

An investigational drug developed by Viridian Therapeutics for the treatment of active thyroid eye disease.

Got photos? Submit your photos here. ›

What they’re saying

“We are very encouraged by the positive results from the REVEAL-1 trial, which demonstrate the potential of Elegrobart to address the significant unmet need for effective treatments for active thyroid eye disease.”

— Jonathan Violin, President and CEO of Viridian Therapeutics

What’s next

Viridian plans to submit a New Drug Application to the U.S. Food and Drug Administration for Elegrobart later this year.

The takeaway

The successful Phase 3 trial of Elegrobart represents an important milestone in the development of a new treatment option for patients with active thyroid eye disease, a condition that can significantly impact quality of life.